|
|
MultiCell is a
leading-edge biopharmaceutical company committed to the development and
commercialization of breakthrough therapeutics based on a portfolio of new
drug candidates and patented drug development technology platforms.
MultiCell leverages patented methods of modulating the human immune system
to treat serious autoimmune diseases, including multiple sclerosis and
type-1 diabetes, as well as influenza and other health threats.
Currently, the market for therapies addressing such conditions is estimated
at $8 billion worldwide.
The Company's novel technologies include expertise in Toll-like receptors
and T-cell targeting to modulate both the
innate and adaptive immune systems, enabling the creation of advanced drug
candidates that stimulate or suppress the immune system via
disease-specific targeting of the immune system.
|
